AstraZeneca has announced that it will sell the Airsupra albuterol / budesonide MDI directly to US patients through a web site called AstraZeneca Direct starting October 1, 2025. According to the company, patients with a prescription will pay “up to 70% off list price” for home delivery of the inhaler, which was approved by the FDA in January 2023 for the treatment of asthma.
AstraZeneca launched AirSupra in the US in January 2024, and the FDA recently approved an sNDA to update the label for the MDI, adding data related to the treatment of mild asthma. In addition to Airsupra, the AstraZeneca Direct site will also allow orders for several other products, including FluMist intranasal influenza vaccine, which was approved for self-administration in September 2024.
AstraZeneca US Country President Joris Silon commented, “We remain deeply committed to improving accessibility, affordability, and driving innovation in healthcare and we are excited to launch AstraZeneca Direct, which will give patients a transparent cash price with the convenience of home delivery. The program complements our existing patient support services and is an important step forward in offering patients the medication they need, when and how they need it.”
Read the AstraZeneca press release
